


MaaT Pharma

Boosting Survival Through Innovative Immune Modulation

October 2025



Disclaimer

This document has been prepared by MaaT Pharma (the "Company") and is for information and background purposes only.

While the information contained herein has been prepared in good faith, neither the Company, nor its shareholders, directors, officers, agents, employees, or advisors give, have given or have authority to give, any representations or warranties (express or implied) as to, or in relation to, the fairness, accuracy, reliability or completeness of the information in this document, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers, including financial information (all such information being referred to as "Information"), and liability therefor is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees, affiliates, representatives or advisers take any responsibility for, or will accept any liability whether direct or indirect express or implied, contractual, tortuous, statutory or otherwise, in respect of the accuracy or completeness of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising from this document.

The information and opinions contained in this document are provided as of the date of this document only and may be updated, supplemented, revised, verified or amended, and thus such information may be subject to significant changes. The Company is not under any obligation to update the information or opinions contained herein which are subject to change without prior notice.

The information contained in this document has not been subject to independent verification and are qualified in their entirety by the business, financial and other information that the Company is required to publish in accordance with the rules, regulations and practices applicable to companies listed on the regulated market of Euronext in Paris, including in particular the risk factors and other information in the Company's Document d'enregistrement (Registration Document) registered by the French Autorité des marchés financiers (Financial Markets Authority) (the "AMF") on October 1st, 2021 under no. I.21-0057 and its supplement on October 14, 2021 under no. I.21-0061 and in any other periodic report, which are available free of charge on the websites of the Company (<https://www.maatpharma.com/>) and the AMF (www.amf-france.org).

No representation, warranty or undertaking, express or implied, is made as to the accuracy, completeness or appropriateness of the information and opinions contained in this document. The Company, its subsidiaries, its advisors and representatives accept no responsibility for and shall not be held liable for any loss or damage that may arise from the use of this document or the information or opinions contained herein.




This document contains information on the Company's markets and competitive position, and more specifically, on the size of its markets. This information has been drawn from various sources or from the Company's own estimates which may not be accurate and thus no reliance should be placed on such information. Any prospective investors must make their own investigation and assessments and consult with their own advisers concerning any evaluation of the Company and its prospects, and this document, or any part of it, may not form the basis of or be relied on in connection with any investment decision.

This document contains certain forward-looking statements. These statements are not guarantees of the Company's future performance. These forward-looking statements relate to the Company's future prospects, developments and marketing strategy and are based on analyses of earnings forecasts and estimates of amounts not yet determinable.

Forward-looking statements are subject to a variety of risks and uncertainties as they relate to future events and are dependent on circumstances that may or may not materialize in the future. Forward-looking statements cannot, under any circumstance, be construed as a guarantee of the Company's future performance and the Company's actual financial position, results and cash flow, as well as the trends in the sector in which the Company operates, may differ materially from those proposed or reflected in the forward-looking statements contained in this document. Even if the Company's financial position, results, cash-flows and developments in the sector in which the Company operates were to conform to the forward-looking statements contained in this document, such results or developments cannot be construed as a reliable indication of the Company's future results or developments. The Company does not undertake any obligation to update or to confirm projections or estimates made by analysts or to make public any correction to any prospective information in order to reflect an event or circumstance that may occur after the date of this document.

All persons accessing this document are deemed to agree to all the limitations and restrictions set out above.

Mã
lật



Company Overview

MaaT013 (Xervyteg®) in aGvHD: Achieved Primary Endpoint of Phase 3 Study Registration in Europe Will Spearhead Microbiome Therapies in Oncology



Xervyteg® Moving Closer to Commercial Launch

- > **Positive Pivotal Phase 3 data with primary endpoint achieved**
(GI-ORR of 62%)
- > **MAA under review in Europe with EMA**
- > **Commercialization Partnership With Clinigen** in acute Graft-versus Host Disease in Europe



Multi-assets platform focused on oncology

- > **Shared foundation to develop full-ecosystem, donor-derived and AI-powered co-cultured candidates**
- > **2 clinical** and 1 preclinical assets
- > **Largest European cGMP** production facilities for Microbiome Ecosystem Therapies™



Financial Overview



- > **Cash position** of **€15m** as of June 30, 2025. **Cash runway** extended to end of **February 2026**, with the upfront of 10.5m€ from Clinigen and the Tranche A of 3.5m€ of the EIB (not included in the June 30, 2025 cash position)
- > **Exploring additional funding options (non dilutive and/or dilutive)** for future developments

Leveraging Microbiome Modulation in Oncology: Mechanisms for Enhanced Survival Outcomes in Multiple Settings

Expected benefits



Xervyteg®

Control of inflammation and restoration of gut integrity

Smith PM et al, Science 2013; Sun M et al, Nat Commun 2018; Gaudier E et al, AJPGLP 2004; Furusawa Y et al, Nature 2013; Arpaia N et al, Nature 2013; Mathewson ND et al, Nat Immunol 2016



MaaT033

Reduction of transplant-related complications

Jenq RR et al, Biol Blood Marrow Transplant 2005; Taur Y et al, Blood J Am Soc Hematol 2014



MaaT034

Optimization of anti-tumor immunity

M. Vetizou et al, Science 2015; Spencer et al, Science 2021; Mager et al., Science 2020

Dysbiosis & disease

- Loss of microbial **diversity**
- Increase in **pathogens**
- Reduction of **microbial metabolites**
- Associated with **multiple conditions**

**Restoration of microbiota diversity
and production of functional metabolites**

**Resolution
of aGvHD**



**Improved
survival in
Allo-HSCT**



**Enhanced
response to
ICI**



Oncology-Focused Platform Fueling a Deep Pipeline of Drug Candidates



Native Ecosystem

Driving near-term value with the donor-derived MET-N platform

Xervyteg®

MaaT033

Co-cultured Ecosystem

Progressing next-generation co-cultured scalable MET-C platform

MaaT034

MaaT03X

Integrated Production

Leading capabilities in full ecosystem microbiome drug production




Capacity: ~11,000 treatable patients per year



PROPRIETARY POOLING APPROACH

Xervyteg®MaaT033

Pooled microbiota → Maximized richness → Standardized (450 OTU ± 3%)



Europe’s Largest Facility Dedicated to Microbiome Ecosystem Therapies™ powers our integrated production of a premier portfolio of native and co-cultured treatments—designed for seamless scalability

A Strong Pipeline With Multiple Value Inflection Milestones and a Close-to-Market Asset




Program	Indication	Market potential	Preclinical	Phase 1	Phase 2	Phase 3	MAA	Status	Recent or Upcoming milestones
Xervyteg®  ↗	aGvHD	~250m€ 1L : 10k patients ² 2L : 5K patients ^{2,3} 3L : 3K patients ^{2,3}	ARES → EAP (EU/US) ongoing: 173 pts treated					Primary endpoint met ★ Ongoing	EU MAA currently under review Updated data at EHA 2025 Congress ✓
	ICI improvement Melanoma	Exploratory	IST* - PICASSO →					Fully recruited	Results H2.25
MaaT033  ↗	Allo-HSCT	~500m€ 6k patients ²	PHOEBUS →					Ongoing	Positive DSMB / Unblinded Safety Readout ✓
	ICI improvement NSCLC	Exploratory	IST** - IMMUNOLIFE →					Pending	FPI expected in H2.25
	ALS	Exploratory	IASO →					Primary endpoint met	Promising Full Data - May 2025 ✓
MaaT034 → IO		~1 to 5b€ ¹ 500k patients	PrClin →						Targeting FIH 2026

aGvHD: acute Graft versus Host Disease ; IO: Immuno-Oncology ; PoC: Proof of Concept; Allo-HSCT: Allogeneic Hematopoietic Stem Cell Transplantation ; ALS: Amyotrophic Lateral Sclerosis ; IST: Investigator Sponsored Trial; NSCLC: Non-small cell lung cancer - ICI PICASSO: ipilimumab (Yervoy®) and nivolumab (Opdivo®) ; ICI IMMUNOLIFE: cemiplimab

* R&D partners include AP-HP, Institut Gustave Roussy

** Institut Gustave Roussy, INSERM, Université Paris-Saclay, Bioaster, INRAe, IHU Méditerranée Infection

Ma
bât



Xervyteg[®]
in aGvHD



Understanding and Addressing Acute Graft-versus-Host Disease (aGvHD)


Donor immune cells recognize the recipient's tissues as foreign, leading to an immune-mediated attack

Skin GvHD



Skin: Rash, itching

Liver GvHD



Jaundice, liver dysfunction/failure

GI GvHD



Severe diarrhea, abdominal pain

- > **Observed in approximately 50% Allo-HSCT Patients**
- > GvHD is characterized by **intestinal dysbiosis associated with higher mortality²**




> 11,000 GvHD Patients / year

Treatment Paradigm

- > 1st Line treatment: Corticosteroids
- > 2nd Line treatment: Ruxolitinib approved for SR-aGvHD
- > 3rd Line treatment: **No approved therapy**
- > Off label Best Available Therapies (BAT) have shown limited benefit

Lack of effective 3rd line therapy



85%

1 year mortality in 3L+

median survival
of **28 days** and
15% OS at 1-year¹



Around 3,000 per year EU/US



Xervyteg®: A Standardised, Pooled, Allogeneic Microbiota Medicine Currently Under Review by the EMA



Orphan Drug Designation
from **FDA and EMA**

01

Characteristics: Pooled allogeneic faecal microbiota

- ✓ Full ecosystem
- ✓ High-diversity (including richness)
- ✓ Large choice of species to patients → Enhance engraftment
- ✓ Each drug product bag must contain not less than 1.35×10^{11} viable bacteria per dose

02

Clinical Signals

- ✓ Over 250 patients treated to date
- ✓ Remarkable efficacy results
- ✓ Positive benefit/risk profile



**PROPRIETARY POOLING
APPROACH**



Xervyteg® (MaaT013)


Pooled microbiota

- Maximized richness
- Standardized (450 OTU ± 3%)

ARES: a Pivotal Phase 3 Trial Exploring Xervyteg® in Third-Line aGvHD Following Steroid and Ruxolitinib Failure



Milestones: *Topline results* announced **January 8th 2025** / **EMA MAA** filed on **June 2nd, 2025** / OS expected by end of 2025






ARES: Strong Response to Xervyteg® in aGvHD Following Steroid and Ruxolitinib Failure

Topline Results

D28 Response Rate (%)



- **62% GI-ORR** with high CR and VGPR rates
- **64% ORR** demonstrating a global systemic response

“These outcomes underscore the curative role of microbiota-based therapies in achieving durable responses leading to prolonged survival. As MaaT013 gains adoption in Europe, it has the potential to redefine care standards for patients facing this life-threatening complication.”

Prof. Malard, MD, hematology professor at Saint-Antoine Hospital and Sorbonne University, lead investigator for the Phase 3 ARES trial




The study met its primary endpoint with a significant gastrointestinal **overall response rate (p < 0.0001)**




ARES: Unprecedented Probability of Survival Compared to Historical Data with Best Available Therapy (BAT)

Overall Survival, ARES vs BAT



Probability of Survival by D28 Response



Xervyteg® demonstrates response-driven prolonged survival, far exceeding expected outcomes in third-line aGvHD, with **54% probability of survival at 1 year compared to 15% survival in historical control**






Key Takeaways

Xervyteg[®], a potential triple first

- 1st Microbiota Therapy in Europe (submission)
- 1st Microbiota Therapy in Oncology Worldwide
- 1st Treatment for Third- line GI-aGvHD

MaaT033



MaaT033 in allo-HSCT




Phoebus: MaaT033 Phase 2b RCT

Potential Adjunctive Treatment for Patients Receiving Allo-HSCT



Design presented at EBMT, SOHO and ASH



Largest Microbiome RCT trial in oncology

- Multicenter Randomized Control Trial
- 56 sites / 6 countries

- Primary endpoint: **1y-OS**
- Results: exp. Q4-2027
- **Dec 24: 80 patients** (LPI target date: mid-26)



Ongoing Phase
2b PHOEBUS






April 2025: Positive Unblinded
Interim Analysis by DSMB
(n=60) – Trial To Continue as
Planned



Based on expected
duration of recruitment,
OS primary endpoint
expected in 2027



~ 6k patients
per year



Commercial And Distribution Strategy in Hemato- Oncology

Leadership in Hemato-Oncology Across the Full Care Continuum of HSCT

Unique Value Proposition

- Unique immunosuppressant-sparing, microbiome-based treatment option in aGvHD
- Well defined **target population** for both products
- Prescribers are **concentrated** on limited number of centers, part of them already using Xervyteg® in the EAP
- **Proven efficacy and safety** with potential to expand to other dysbiosis-associated hematological malignancies (e.g., CAR-T)
- Multiple short-term value catalysts within next few months

Significant opportunity to leverage partner's expertise in hematology, rare diseases, and hospital commercial operations.

A Significant Market Opportunity

Xervyteg®
~€250m¹



3rd line
a-GvHD

👤 3L: ~ 2,000-2,400 patients²
Curative approach

MaaT033
~€500m^{€1}




Improvement
of survival for
allo-HSCT

👤 ~6,000 patients²



A Total market of
~€750 m+

Licensing Late Stage Asset Xervyteg® to Clinigen for Commercialization in Europe



This commercial and distribution agreement in **Europe** is a **benchmark** for future agreements in other regions such as **Asia, Middle East and beyond**, for both **MaaT013** and **MaaT033**

Synergy with Purpose: Growth Driven by Patient-Centric Collaboration



Commercialization

- MaaT Pharma will manufacture and supply the product to Clinigen. If approved, MaaT Pharma to hold the Marketing Authorization.
- Leveraging on its large footprint and solid knowledge of Hemato-oncology, Clinigen will manage commercialization i.e. marketing, promotion and distribution of Xervyteg®.

Scope of the Collaboration

EU27 + Iceland, Norway, Liechtenstein and the United Kingdom



Early Access Program

- Clinigen will start managing the Early Access Program in Europe, building on MaaT Pharma long standing experience. This will allow MaaT Pharma staff to focus more on Clinical/Regulatory activities.

CLINIGEN



Market access
Early Access Program
KOL engagement
Large hospital networks



**Ma
aT**



Discovery
Clinical development
Regulatory milestones
Industrial scale-up

Bringing Xervyteg® to Market:

Financial terms of the Commercial Partnership for Europe

 **Financial Terms**

Upfront payment	Regulatory & Sales milestones	Royalties on net sales	Drug Supply
10.5M€	Up to 18M€	Mid-thirties	Set Cost Terms

 **European Market for Xervyteg®**

Total Adressable Population in 3L aGvHD*	Patients Treated at peak*	Expected Yearly Peak Sales*	Potential revenues generation
Ca. 1.900	1.200 – 1.600	between 75-100M€	H2 2026 If approved


**MaaT Pharma’s estimates*

Extending cash runway through **non-dilutive upfront payment** while securing sustained funding through milestone payments and recurring revenues.

Early Access Program in Europe will Transition to Clinigen

Supplying The Increasing International Demand

Number of patients



Clinical Outcome

- **252 requests** and **173 GvHD patients** analyzed as of October 2024 and presented at **EHA 2025**:
 - Efficacy (All lines) = GI-ORR at D28: **53%**; 1Y OS: **48%**
 - Efficacy (3L) = GI-ORR at D28: **57%**; 1Y OS: **51%** consistent with ARES data :
 - ARES Data = GI-ORR at D28: **62%**; 1y OS: **54%**
 - Safety = Favorable B/R ratio
- Product positioning in third-line (3L) aGvHD




Today with MaaT Pharma, Tomorrow with Clinigen

CLINIGEN

Today - Supply chain & Manufacturing

- Xervyteg® shipped to 10 countries
- 2 distribution centers: Horsham (USA) & Bordeaux (France)



Tomorrow with Clinigen in Europe

- **Leverage the infrastructure of Clinigen, in Europe, from day one.**
- **Boost adoption and expand patient access.**



Largest European cGMP Manufacturing Facility for Microbiome Ecosystem Therapies™



Xervyteg®

9,000 products/year ; 3,000 patients/year

MaaT033

1,300,000 capsules/year ; 6,000 patients / year




MaaT03X

Up to 300,000 capsules/year

Leading microbiome therapies fully integrated manufacturing and development platform: streamlined product development, scaleup and GMP process.

Partnership with






Future Growth Drivers in Immuno- Oncology

Unlocking the Potential of Checkpoint Inhibitors: How Full-Ecosystem Gut Microbiome Overcomes Primary Resistance

Immune Checkpoint Inhibitors (ICI) significantly improve outcomes in solid tumor patients

Primary Resistance Rate to ICIs



Lung Cancer (NSCLC)

35 - 40 %



Skin Cancer (Melanoma)

Up to 65 %

→ Urgent need for new ICI combination therapies to boost response rates and survival

Leveraging full ecosystem microbiome could be a game-changer in immuno-oncology

2021: FMT from ICI-responders could overcome resistance to ICI in non-responders with metastatic melanoma



6/15

Non-responders -> Responders
(Davar et al, 2021)



3/10

Non-responders -> Responders
(Baruch et al, 2021)

2023: Microbiotherapy from healthy donors boosts response to aPD1+aCTLA4 in ICI-naïve metastatic melanoma patients



15/20

ICI-naïve → Responders
(ORR=75 %, Routy, 2024)



.../35

PICASSO studying
Xervyteg®: 1st multicenter
RCT **70 pts rand 1:1**

From Proof to Platform: An Integrated IO Strategy

Coordinated development path leveraging on proven safety profile of Xervyteg® while optimizing MaaT034



MET-N

Xervyteg® MaaT033

Full High Diversity
Ecosystem
Microbiota



Phase 3 validated



Enhancement/
Optimization of HSCT

Xervyteg® Evaluated in Phase 2a Randomized, Multicenter Clinical Trial in Melanoma

PICASSO, PoC trial, fully recruited (n=70)

Data expected in H2.25 - Investigator Sponsored Trial

(Assistance Publique - Hôpitaux de Paris) in collaboration w/ Institut
Gustave Roussy

Two positive DSMBs

Key study endpoints after 23 weeks of treatment: **safety profile and
best-overall response rate** vs placebo as add-on treatment to
Ipilimumab + Nivolumab

1

Microbiome-based
Immunomodulation

2

Manufacturing
Expertise

3

Synergy with
Immunologically
Active Therapies

4

Translational
continuity



MET-C

MaaT03X

Rationally Selected
Microbial Ecosystems




Targeted Metabolite
Production




Synergies with
Immunotherapies

MaaT034 boosts anti-PD1 effect A) reducing tumor size & B) increasing survival compared to single strains like *A. Muciniphila*




A) Tumor Size Evolution



B) Survival Rate



Legend:
- - - Germ-free - - - MaaT034 - - - *A. muciniphila*
— anti-PD1 — MaaT034 + anti-PD1 — *A. muciniphila* + anti-PD1



Looking Ahead & Key Takeaways

Several Major Near-Term Value Inflection Expected Milestones

2025

2026

2027

Partnered

Xervyteg® | GvHD   

Ares Ph3 28 days GI-ORR **results Jan 25**

MA **application** EMA **June 25**

Ares Ph3 OS **results H2 25** **CLINIGEN**

MaaT033 | allo HSCT 

Phoebus Ph2b DSMB **H1 25**

Phoebus Ph2b DSMB **Q3 25**

Xervyteg®   

GvHD | MA **approval** EMA **H2 26** **CLINIGEN**

Xervyteg®  

GvHD | Potential pivotal Ph3 FPI **26**

MaaT033 

HSCT | Phoebus Ph2b **LPI Mid 26**

MaaT033   

HSCT | Phoebus Ph2b OS **results H2 27**

Xervyteg® 

Melanoma | IST Picasso Ph2a **results H2 25**

MaaT033 

NSCLC | IST Immunolife Ph2a FPI **H2 25**

MaaT034 

IO | 1st clinical batch produced **H2 25**

MaaT033 

NSCLC | IST Immunolife Ph2a **interim analysis reviewed by IDMC Q4 26**

MaaT034 

IO | FIH Solid tumor **26**

Hemato
-
Oncology

Immuno
-
Oncology

Key takeaways on MaaT Pharma

Progress of the Pipeline

- **Leadership in Hemato-Oncology** through immune modulation with microbiome-derived therapies **across all treatment stages**
- **Exploring Immuno-Oncology** preclinically with **MaaT034 with strong anti-tumor activity** coupled with ICI and Clinically with **PoC with PICASSO using Xervyteg®**

Commercial and Distribution Strategy

- **Clinigen** will manage commercialization, marketing & promotion of Xervyteg®, **MaaT Pharma** will manufacture and supply the product and, if approved, will hold the Marketing Authorization
- **MaaT033, with greater market potential**, is positioned for similar deals, pending data maturation to **secure optimal terms**

Financial Figures

- **Cash position** of €15m as of June 30, 2025
- **Cash runway** extended into **February 2026**, with the upfront of 10.5m€ from Clinigen & EIB Tranche A funding
- **37.5m€ loan from European Investment Bank (EIB) in four tranches** (€3.5m for Tranche A, €6.0m for Tranche B, €8.0m for Tranche C, and €20.0m for Tranche D) subject to operational and financing conditions.
- **Exploring additional funding options (non dilutive and/or dilutive)** for future developments

**Leading the Field
in Microbiome-
Driven Immune
Modulation**

Corporate Social Responsibility



MaaT Pharma is a leading, late-stage clinical company committed to advancing gut microbiome science to deliver safe, sustainable, and innovative therapies that **modulate the immune system and improve outcomes for cancer patients.**



Patients are the priority. MaaT Pharma is committed to patients and to the protection of human health by respecting the environment, valuing its employees, and ensuring good governance practices.

MaaT Pharma’s core values are guided by the following four principles:

- Innovate and raise awareness to **deliver better care,**
- Foster employee growth within a **people-oriented ecosystem,**
- Place **ethics and transparency** at the core of the Company’s strategy,
- Control and measure **the Company’s environmental impact.**

2024 CSR indicators

Social

37 y-o

is the average age of permanent employees

17

permanent employees under 30 years old (as of 12/31/24)

94%

Training Plan Completion Rate

Environment

7603 tCO2e

Carbon footprint

248 kWh /Employee

Energy consumption per employees on site

Societal

81%

of operating expenses related to R&D as a proportion of total operating expenses

290

public interventions to increase awareness on microbiome

Governance

43%

of women in the Board of directors




57%

of independents in the Board of directors

55%

of women in the Executive team

Ma
pât



Thank you

